News from Weill Cornell Medical College
Dr. Laurie H. Glimcher Honored by Female Scientists from The Feinstein Institute for Medical Research for Excellence in Immunology Research
May 20, 2013 Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is the winner of a prestigious award from a group of female scientists from The Feinstein Institute for Medical Research dedicated to celebrating outstanding women in science and medicine. [more]
More Press Releases
Weill Cornell's Dr. John P. Leonard Leads National Cancer Institute's Alliance for Clinical Trials in Oncology Lymphoma Committee
May 16, 2013 Dr. John Leonard, an internationally-recognized hematology and oncology expert specializing in the treatment of lymphomas at Weill Cornell Medical College, has been named chair of the Lymphoma Committee for the prestigious National Cancer Institute-sponsored group, the Alliance for Clinical Trials in Oncology. Dr. Leonard is the associate dean for clinical research at Weill Cornell and director of the Joint Clinical Trials Office at Weill Cornell and NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
May 16, 2013 Dr. John Leonard, an internationally-recognized hematology and oncology expert specializing in the treatment of lymphomas at Weill Cornell Medical College, has been named chair of the Lymphoma Committee for the prestigious National Cancer Institute-sponsored group, the Alliance for Clinical Trials in Oncology. Dr. Leonard is the associate dean for clinical research at Weill Cornell and director of the Joint Clinical Trials Office at Weill Cornell and NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Researchers Discover Master Regulator That Drives Majority of Lymphoma
May 13, 2013 A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients.
May 13, 2013 A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients.
